MX2023003556A - Composiciones farmaceuticas. - Google Patents
Composiciones farmaceuticas.Info
- Publication number
- MX2023003556A MX2023003556A MX2023003556A MX2023003556A MX2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- active pharmaceutical
- pharmaceutical ingredient
- nilotinib
- adsorbent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 abstract 1
- 239000003463 adsorbent Substances 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001346 nilotinib Drugs 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan composiciones farmacéuticas que incluyen una mezcla de un ingrediente farmacéutico activo lipofílico tal como nilotinib, un polímero hidrofílico, uno o más de tensoactivos, y de manera opcional un adsorbente. También se describen métodos para la preparación y el uso de tales composiciones farmacéuticas. En un aspecto, se describe en la presente una dispersión sólida amorfa que comprende el ingrediente farmacéutico activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020118608 | 2020-09-29 | ||
PCT/CN2021/121695 WO2022068876A1 (en) | 2020-09-29 | 2021-09-29 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003556A true MX2023003556A (es) | 2023-06-13 |
Family
ID=80951208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003556A MX2023003556A (es) | 2020-09-29 | 2021-09-29 | Composiciones farmaceuticas. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20230414613A1 (es) |
EP (1) | EP4221690A1 (es) |
JP (1) | JP2023543815A (es) |
KR (1) | KR20230097021A (es) |
CN (1) | CN116635015A (es) |
AU (1) | AU2021353684A1 (es) |
CA (1) | CA3193829A1 (es) |
MX (1) | MX2023003556A (es) |
WO (1) | WO2022068876A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114869853A (zh) * | 2022-05-25 | 2022-08-09 | 济宁医学院 | 一种柚皮素固体分散体及其制备方法 |
WO2023235267A2 (en) * | 2022-05-28 | 2023-12-07 | Avalyn Pharma Inc. | Nintedanib and nintedanib combination dry powder compositions and uses |
WO2024142002A1 (en) * | 2022-12-29 | 2024-07-04 | Renata Pharmaceuticals (Ireland) Limited | Pharmaceutical suspension of nilotinib |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
CN106932522A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种尼罗替尼中杂质化合物i含量的测定方法 |
CN113573712A (zh) * | 2019-02-18 | 2021-10-29 | 斯莱班克制药有限责任公司 | 尼洛替尼的药物组合物 |
-
2021
- 2021-09-29 CA CA3193829A patent/CA3193829A1/en active Pending
- 2021-09-29 KR KR1020237014087A patent/KR20230097021A/ko unknown
- 2021-09-29 JP JP2023519417A patent/JP2023543815A/ja active Pending
- 2021-09-29 WO PCT/CN2021/121695 patent/WO2022068876A1/en active Application Filing
- 2021-09-29 CN CN202180076129.9A patent/CN116635015A/zh active Pending
- 2021-09-29 AU AU2021353684A patent/AU2021353684A1/en active Pending
- 2021-09-29 MX MX2023003556A patent/MX2023003556A/es unknown
- 2021-09-29 EP EP21874531.3A patent/EP4221690A1/en active Pending
-
2023
- 2023-03-28 US US18/191,637 patent/US20230414613A1/en active Pending
-
2024
- 2024-03-19 US US18/609,790 patent/US20240226102A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022068876A1 (en) | 2022-04-07 |
US20240226102A1 (en) | 2024-07-11 |
EP4221690A1 (en) | 2023-08-09 |
CN116635015A (zh) | 2023-08-22 |
CA3193829A1 (en) | 2022-04-07 |
US20230414613A1 (en) | 2023-12-28 |
KR20230097021A (ko) | 2023-06-30 |
AU2021353684A1 (en) | 2023-06-08 |
JP2023543815A (ja) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003556A (es) | Composiciones farmaceuticas. | |
PH12021550701A1 (en) | Ionizable amine lipids | |
MX2021012934A (es) | Lipidos de amina ionizables y nanoparticulas lipidicas. | |
PH12021551279A1 (en) | Modified amine lipids | |
PL2029121T3 (pl) | Transdermalny system terapeutyczny zawierający cząstki substancji czynnej, o zwiększonym przepływie substancji czynnej | |
NO20074100L (no) | Mikroimplantater for okulaer administrering | |
WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
WO2002074247A3 (en) | Pharmaceutical formulations for sustained release | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2004066910A8 (en) | Controlled release modifying complex and pharmaceutical compositions thereof | |
MX2010004222A (es) | Formulaciones solidas de compuestos cristalinos. | |
WO2007027941A3 (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
PL2046292T3 (pl) | Preparaty eterów benzymidazolilo-pirydylowych | |
WO2011067791A3 (en) | Process for preparing pharmaceutical ophthalmic compositions | |
PE20091949A1 (es) | Formulacion farmaceutica solida con liberacion retardada | |
MXPA05010196A (es) | Nuevas formulaciones y su uso. | |
MX2022007707A (es) | Comprimidos de edoxaban. | |
WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
MD4591C1 (ro) | Dispersie solidă a unui modulator selectiv al receptorului de progesteron | |
MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
CO6270206A2 (es) | Producto de dispersion solida de drogas basadas en n-aril urea | |
WO2005115346A3 (en) | Pharmaceutical composition containing risperidone |